Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,234.6
-19.4 (-0.60%)

 

  • STI Straits Times Index
    3,234.6
    -19.4 (-0.60%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,574.4
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,909.1
    -431.9 (-1.52%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -84.2 (-2.75%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,795.4
    -235.9 (-0.98%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,249.2
    15.8 (0.25%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,246.1
    -21.1 (-0.93%)
    Index delayed 20 minutes
  • XAO XAO
    7,199.0
    -50.0 (-0.69%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,734.1M
  • Value: 1,390.5M
  • Rise: 93
  • Fall: 228
  • Unch: 497

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Reenova Investment^0.003+0.001
Medtecs Intl0.105+0.007
Ntegrator Intl0.015-
Golden Agri-Res0.225-0.005
Rex Intl0.174-0.014
AusGroup^0.039-0.005
YZJ Shipbldg SGD1.060-0.030
OEL0.024-0.005
Singtel3.340+0.060
Jiutian Chemical0.021-0.001

World Indices

World Indices
Name Last Change
Nasdaq 9,383.8 +13.0
HSI 27,909.1 -431.9
HSCEI 10,952.2 -222.5
Jakarta 6,249.2 +15.8
Nikkei 225 23,795.4 -235.9
SSE Comp 2,976.5 -84.2
Shanghai A 3,118.9 -88.2
Shanghai B 248.6 -8.9
PSE Comp 0.0
KOSPI 2,246.1 -21.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

STARPHARMA HOLDINGS LIMITED STARPHARMA HOLDINGS LIMITED
Updated on 23 Jan 2020 (End of trading day)
Last (AUD): 1.195 Change: +0.005 High: 1.200 Remarks: -
Change (%): +0.42 Low: 1.170
Open 1.190 Yesterday's Close 1.1900000000000002
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 292,640 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a -0.03827 Trailing EPS (AUD) e -0.03827 NAV (AUD) b 0.1138
PE a - Trailing PE f - Price / NAV b 10.5009
Dividend (AUD) d - Cash In Hand (AUD) g 0.1107 Issued & Paid-up Shares c 372,484,000
Dividend Yield (%) d - Price / Cash In Hand g 10.795 Treasury Shares h -
Beta - 75 Daysi 0.227 R-Squared - 75 Days(%)i 0.40 Market Cap (M) 445.118
Beta - 500 Daysi 0.632 R-Squared - 500 Days (%)i 1.85 Enterprise Value (M) 403.893
Piotroski F Score 1 Exchange Code SPL Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 32.61 Free Float (%) 92.0
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 05 Dec 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 16 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference STARPHARMA HOLDINGS LIMITED ASX 445.118 - - 10.5009 -
Industry Pharmaceuticals: Major ASX 89.435 - - 7.2898 -
Local Peer AFT PHARMACEUTICALS LTD ASX 301.658 - 29.805 22.2541 -
Local Peer PALLA PHARMA LTD ASX 127.837 - - 2.8039 -
Local Peer MEDLAB CLINICAL LIMITED ASX 78.129 - - 5.1938 -
Local Peer RECCE PHARMACEUTICALS LTD ASX 43.471 - - -108.0645 -
Local Peer NOXOPHARM LTD ASX 31.067 - - -293.7500 -
Local Peer CRESO PHARMA LTD ASX 30.470 - - 1.7378 -
Local Peer EXOPHARM LTD ASX 27.687 - - 5.4104 -
Local Peer RACE ONCOLOGY LTD ASX 24.012 - - 4.7516 -
Local Peer FARMAFORCE LTD ASX 11.589 - - -8.4906 -
Local Peer SUDA PHARMACEUTICALS LTD ASX 7.966 - - 0.5697 -
Local Peer FIJI KAVA LTD ASX 5.926 - - 1.9187 -
Global Peer JOHNSON & JOHNSON NYSE 390,174.727 25.507 27.572 6.7029 2.415
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 240,631.850 19.038 20.370 4.5814 -
Global Peer MERCK & CO INC NYSE 228,247.107 36.696 24.508 8.5046 2.260
Global Peer PFIZER INC NYSE 222,416.283 19.944 13.717 3.4173 3.547
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 158,068.057 32.128 27.795 8.9568 1.654
Global Peer ELI LILLY AND COMPANY NYSE 135,916.144 42.053 31.851 40.1817 1.750
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 132,394.926 61.540 64.545 10.8841 -
Global Peer ABBVIE INC NYSE 128,967.892 22.798 39.941 -15.6782 4.529
Global Peer SANOFI SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 123,879.886 24.312 30.118 1.9304 2.324
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 119,226.492 24.680 20.571 8.2188 -
Other Global Peers NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), SINOPHARM (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CHINARES PHARMA (HKEx), BAIYUNSHAN PH (HKEx), INNOVENT BIO-B (HKEx), ALLAKOS INC (NASDAQ), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), CMS (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), SSY GROUP (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), HENLIUS-B (HKEx), JUNSHI BIO-B (HKEx), CHINAGRANDPHARM (HKEx), RA PHARMACEUTICALS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), FORTY SEVEN INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), ZYMEWORKS INC (NYSE), CANSINOBIO-B (HKEx), TRICIDA INC (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CSTONE PHARMA-B (HKEx), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), UNITED LAB (HKEx), ATHENEX INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), GOSSAMER BIO INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PROVENTION BIO INC (NASDAQ), PETIQ INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), AC IMMUNE SA (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), HUA MEDICINE-B (HKEx), IGBB (Bursa), CRINETICS PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), MIRUM PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), Kimia Farma (Persero) Tbk. (IDX), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), LANNETT CO INC (NYSE), 89BIO INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), EVOLUS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), TOT BIOPHARM-B (HKEx), KALVISTA PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), VERU INC (NASDAQ), DAWNRAYS PHARMA (HKEx), SUTRO BIOPHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), BIOMX INC (NYSE American), IDEAYA BIOSCIENCES INC (NASDAQ), OBSEVA SA (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), NC HEALTHCARE (HKEx), XERIS PHARMACEUTICALS INC (NASDAQ), AKORN INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), ARTARA THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), PHARMA (Bursa), ETON PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), ESSA PHARMA INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), IX Biopharma (SGX), CHARMACY PHAR (HKEx), CHECKPOINT THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), IMMUNIC INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), THE FS ALSEC ALPHASECTOR (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), EYENOVIA INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), NEP INTERLONG (HKEx), AGEX THERAPEUTICS INC (NYSE American), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), BAUDAX BIO INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), ALLENA PHARMACEUTICALS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), Hyphens Pharma (SGX), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), IP (SET), ACER THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), NOVA (Bursa), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), BIOHLDG (Bursa), SANAI HEALTH GP (HKEx), ZOMEDICA PHARMACEUTICALS CORP (NYSE American), EDESA BIOTECH INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), SINOLIFE UTD (HKEx), NOVAN INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), NOVUS THERAPEUTICS INC (NASDAQ), Merck Sharp Dohme Pharma Tbk. (IDX), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), EMINENCEENT RTS (HKEx)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.025
-2.05 %
10 Days --0.010
-0.83 %
20 Days --0.005
-0.42 %
Medium Term Return 3 Months -+0.065
+5.75 %
6 Months --0.140
-10.49 %
1 Year -+0.080
+7.17 %
Long Term Return 2 Years --0.245
-17.01 %
3 Years -+0.390
+48.45 %
5 Years -+0.750
+168.54 %
Annualised Return Annualised --
+21.84 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.940 - 1.445 Change From 1 Year Low +0.255 % Change From 1 Year Low (%) +27.13
Change From 1 Year High -0.250 % Change From 1 Year High (%) -17.30
2 Years Range 0.870 - 1.670 Change From 2 Years Low +0.325 % Change From 2 Years Low (%) +37.36
Change From 2 Years High -0.475 % Change From 2 Years High (%) -28.44
5 Years Range 0.430 - 1.670 Change From 5 Years Low +0.765 % Change From 5 Years Low (%) +177.91
Change From 5 Years High -0.475 % Change From 5 Years High (%) -28.44
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Its programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Jan 2020 1.175 1.190 1.160 1.190 101,621 -
21 Jan 2020 1.175 1.180 1.160 1.180 117,022 -
20 Jan 2020 1.180 1.180 1.170 1.175 144,626 -
17 Jan 2020 1.190 1.195 1.180 1.190 234,140 -
16 Jan 2020 1.220 1.220 1.182 1.190 101,705 -
15 Jan 2020 1.195 1.220 1.180 1.220 185,882 -
14 Jan 2020 1.200 1.225 1.180 1.220 282,003 -
13 Jan 2020 1.185 1.195 1.150 1.180 165,061 -
10 Jan 2020 1.170 1.210 1.170 1.200 94,947 -
09 Jan 2020 1.190 1.200 1.170 1.190 195,612 -
08 Jan 2020 1.190 1.212 1.170 1.205 132,758 -
07 Jan 2020 1.215 1.230 1.190 1.190 89,238 -
06 Jan 2020 1.220 1.220 1.185 1.200 231,889 -
03 Jan 2020 1.220 1.245 1.215 1.215 72,566 -
02 Jan 2020 1.230 1.245 1.220 1.220 82,548 -
31 Dec 2019 1.235 1.235 1.210 1.210 21,608 -
30 Dec 2019 1.205 1.235 1.195 1.235 263,144 -
27 Dec 2019 1.210 1.210 1.195 1.195 19,103 -
24 Dec 2019 1.230 1.230 1.180 1.200 81,306 -
23 Dec 2019 1.250 1.250 1.170 1.230 213,056 -
20 Dec 2019 1.245 1.245 1.220 1.220 144,801 -
19 Dec 2019 1.280 1.280 1.210 1.245 234,545 -
Summary
Current 2 Weeks
(09 Jan 2020 to 22 Jan 2020)
1.190 1.225 1.150 1.190 1,622,619 -
Previous 2 Weeks
(23 Dec 2019 to 08 Jan 2020)
1.250 1.250 1.150 1.205 1,207,216 -
4 Weeks from
(25 Nov 2019 to 20 Dec 2019)
1.320 1.340 1.150 1.220 9,523,229 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.